Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Table 1

Demographic and baseline characteristics and compliance by treatment group (intention-to-treat population).

Characteristic	Treatment group
	Placebo (𝑛=253)	CVT-E002 400 mg (𝑛=249)	CVT-E002 800 mg (𝑛=246)
Age (years)	[232] 71.3 (5.5)	[244] 71.4 (5.5)	[233] 71.6 (7.5)
Sex—female	135/253 (53.4%)	143/249 (57.4%)	108/246 (43.9%)
Smoker	12/251 (4.8%)	15/246 (6.1%)	16/243 (6.6%)
Weight (kg)	[243] 75.9 (14.3)	[241] 75.0 (15.7)	[232] 77.5 (16.7)
Height (cm)	[243] 167.4 (10.3)	[241] 168.5 (11.2)	[233] 169.2 (9.9)
BMI	[243] 27.1 (4.7)	[241] 26.4 (5.1)	[232] 27.0 (5.3)
	Compliance
mean (sd)	77.8 (34.2)	84.9 (27.8)	81.2 (30.5)^a
Number >80% compliant	187 (73.9%)	202 (81.1%)	187 (76.0%)

For continuous variables entries represent mean (sd) and for dichotomous variables frequency/𝑛 (%). [𝑥] denotes 𝑛 for that measure if different than total.
^a𝑃<0.036 Between-group comparisons made using chi-square test for comparing proportions.